Daily Cancer News

OMNI Health Media is a leading online provider of Daily Cancer News. OMNI’s Daily Cancer News provides summaries of new treatment strategies as they are discovered and reported by physicians and scientists around the world. Our mission is to provide this news, including results of recent clinical trials evaluating cancer therapies and supportive care strategies, to better educate patients and their caregivers, ensuring timely access to the best cancer care available.

CancerConnect Cancer Commuity & Discussions

Share


Latest Cancer News


Palbociclib/Letrozole Improves Outcomes of Estrogen Receptor–Positive/HER2-Negative Advanced Breast Cancer (February 27, 2015)

The results of the phase II PALOMA-1/TRIO-18 trial were recently reported in The Lancet Oncology and suggest that the addition of Ibrance® (palbociclib) to Femara® (letrozole) delayed the time to cancer... Continue Reading

Phase II Clinical Trial Shows Stem Cell Transplantation Effective For Severe Multiple Sclerosis Treatment (February 26, 2015)

A study published in the journal Neurology reveals that stem cell transplantation could be a more effective therapy in severe cases of multiple sclerosis (MS) than the drug mitoxantrone. The study is entitled... Continue Reading

FDA Grants Breakthrough Therapy Designation for MPDL3280A, an anti-PDL1 Investigational Cancer Immunotherapy for Non-Small Cell Lung Cancer (February 26, 2015)

CancerConnect News: The investigational cancer immunotherapy MPDL3280A (anti-PDL1) has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA). The designation was granted... Continue Reading

Farydak® Approval Provides Another Treatment Option for Patients With Multiple Myeloma (February 25, 2015)

Novartis announced today that the US Food and Drug Administration (FDA) has approved Farydak® (panobinostat) in combination with Velcade® and dexamethasone for the treatment of patients with multiple... Continue Reading

FDA Approves New Indication for Ibrutinib in Waldenström’s Macroglobulinemia (February 24, 2015)

CancerConnect News: The US Food and Drug Administration (FDA) today expanded the approved use of Imbruvica® (ibrutinib) for patients with Waldenström’s macroglobulinemia, a rare type of B-cell lymphoma.... Continue Reading

New Study Exposes Unmet Needs of Cancer Survivors (February 23, 2015)

CancerConnect News: Cancer survivors can face ongoing physical, financial, and psychological challenges for years after completing treatment. According to a recent study, healthcare providers can improve... Continue Reading

Colorectal Cancer Talk: Are You At High Risk? (February 23, 2015)

Join the Experts for a LIVE Online Video Chat Colorectal cancer screening should begin at age 50 for those at average risk. But what if you have risk factors? How do you know if you’re at greater risk... Continue Reading

Adding Zytiga to Prednisone Improves Survival and Pain in Chemotherapy-Naive Castration-Resistant Prostate Cancer Patients (February 23, 2015)

CancerConnect News: The addition of Zytiga® (abiraterone acetate) to prednisone significantly improves survival of chemotherapy-naive patients whose prostate cancer has become resistant to hormone therapy.... Continue Reading

U.S. FDA Issues Warning about Certain Type of Endoscope (February 20, 2015)

The U.S. Food and Drug Administration (FDA) has issued a Safety Communication about a certain type of endoscope­—specifically the device used in endoscopic retrograde cholangiopancreatography (ERCP).... Continue Reading

Encouraging Overall Survival and Well-Being for Xilonix™ in Advanced Colorectal Cancer (February 19, 2015)

CancerConnect News: The investigational agent Xilonix™ appears safe and effective for patients with advanced colorectal cancer. These findings were presented at the 2015 Gastrointestinal Cancers Symposium,... Continue Reading

Intravenous Administration of Erwinaze® Approved by FDA (February 18, 2015)

CancerConnect News: The U.S. Food and Drug Administration (FDA) recently approved the intravenous administration of Erwinaze® (asparaginase Erwinia chrysanthemi).  Erwinaze is utilized as a component... Continue Reading

AFCR-supported International Collaborative Research Maps Mutations in Gastric Cancer, Paving the Way for Personalized Medicine (February 17, 2015)

CancerConnect News: An international team of research scientists has revealed new genetic insights that could change the way oncologists treat gastric cancer – the fourth most common cancer and the second... Continue Reading

Phase III Trial Finds Jakafi Superior to Standard Therapy for Polycythemia Vera (February 17, 2015)

CancerConnect News: A Phase III trial finds that Jakafi® (ruxolitinib) is more effective than standard therapy for patients with polycythemia vera (PV). These findings were published in the New England... Continue Reading

AMG 337 MET Inhibitor Produces Impressive, Rapid Response in Gastric and Esophageal Cancers (February 12, 2015)

AMG 337 is a novel small-molecule MET inhibitor that appears to show promise in the treatment of MET-amplified gastroesophageal junction, gastric, and esophageal cancers. MET inhibitors are a class of... Continue Reading

NFCR-Support Research Finds New Way to Combat Resistant Lung Cancer (February 11, 2015)

A team of researchers at Massachusetts General Hospital has developed a new platform that can rapidly identify effective drug combinations for lung cancer patients whose tumors have stopped responding... Continue Reading

Addition of Linifanib to Carboplatin-Paclitaxel Increases Progression-Free Survival and Toxicity in Advanced Nonsquamous NSCLC (February 10, 2015)

In a phase II trial reported in the Journal of Clinical Oncology doctors reported that the addition of linifanib to carboplatin-paclitaxel chemotherapy the outcomes in patients with advanced nonsquamous... Continue Reading

Melanoma Research Alliance Reports Wendy Selig to Step Down as President and CEO (February 9, 2015)

CancerConnect News:  The Melanoma Research Alliance (“MRA”) announced today that Wendy Selig has informed its Board of Directors of her plan to step down as President and CEO, posts she has held... Continue Reading

New Research Concludes that Majority of Cancers Are “Bad Luck”—or Random Mutations (February 9, 2015)

According to recent research, the majority of cancers are caused by random mutations in cell DNA during stem cell division, as opposed to lifestyle, inherited, or environmental risk factors. These findings... Continue Reading

More Cancer News

CancerConnect Cancer Commuity & Discussions


Cancer Types



Headline News by Cancer Type


Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS